Charles Schwab’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.37M | Buy |
886,987
+60,692
| +7% | +$436K | ﹤0.01% | 2228 |
|
|
2025
Q1 | $4.95M | Sell |
826,295
-6,860
| -0.8% | -$41.1K | ﹤0.01% | 2275 |
|
|
2024
Q4 | $6.5M | Buy |
833,155
+7,362
| +0.9% | +$57.4K | ﹤0.01% | 2214 |
|
|
2024
Q3 | $8.92M | Buy |
825,793
+139,096
| +20% | +$1.5M | ﹤0.01% | 2079 |
|
|
2024
Q2 | $5.79M | Buy |
686,697
+67,661
| +11% | +$570K | ﹤0.01% | 2295 |
|
|
2024
Q1 | $4.16M | Buy |
619,036
+13,007
| +2% | +$87.4K | ﹤0.01% | 2348 |
|
|
2023
Q4 | $3.56M | Buy |
606,029
+13,537
| +2% | +$79.6K | ﹤0.01% | 2451 |
|
|
2023
Q3 | $5.78M | Buy |
592,492
+397,765
| +204% | +$3.88M | ﹤0.01% | 2187 |
|
|
2023
Q2 | $2.31M | Buy |
194,727
+19,294
| +11% | +$228K | ﹤0.01% | 2504 |
|
|
2023
Q1 | $1.89M | Buy |
175,433
+4,128
| +2% | +$44.5K | ﹤0.01% | 2540 |
|
|
2022
Q4 | $1.98M | Buy |
171,305
+2,926
| +2% | +$33.8K | ﹤0.01% | 2573 |
|
|
2022
Q3 | $2.51M | Buy |
168,379
+55,184
| +49% | +$824K | ﹤0.01% | 2519 |
|
|
2022
Q2 | $1.02M | Buy |
113,195
+15,418
| +16% | +$139K | ﹤0.01% | 2788 |
|
|
2022
Q1 | $733K | Hold |
97,777
| – | – | ﹤0.01% | 2974 |
|
|
2021
Q4 | $839K | Buy |
97,777
+3,886
| +4% | +$33.3K | ﹤0.01% | 2970 |
|
|
2021
Q3 | $790K | Sell |
93,891
-60
| -0.1% | -$505 | ﹤0.01% | 2967 |
|
|
2021
Q2 | $762K | Buy |
+93,951
| New | +$762K | ﹤0.01% | 3021 |
|
|
2019
Q2 | – | Sell |
-9,548
| Closed | -$168K | – | 3228 |
|
|
2019
Q1 | $168K | Hold |
9,548
| – | – | ﹤0.01% | 3044 |
|
|
2018
Q4 | $169K | Buy |
+9,548
| New | +$169K | ﹤0.01% | 3038 |
|